Aquestive Therapeutics Inc (AQST)
3.52
+0.24
(+7.32%)
USD |
NASDAQ |
May 03, 16:00
3.51
-0.01
(-0.28%)
After-Hours: 20:00
Aquestive Therapeutics Enterprise Value: 261.68M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 261.68M |
| May 02, 2024 | 244.09M |
| May 01, 2024 | 250.32M |
| April 30, 2024 | 249.95M |
| April 29, 2024 | 277.44M |
| April 26, 2024 | 301.99M |
| April 25, 2024 | 291.73M |
| April 24, 2024 | 289.53M |
| April 23, 2024 | 317.39M |
| April 22, 2024 | 324.72M |
| April 19, 2024 | 304.56M |
| April 18, 2024 | 333.51M |
| April 17, 2024 | 291.00M |
| April 16, 2024 | 285.87M |
| April 15, 2024 | 292.46M |
| April 12, 2024 | 290.27M |
| April 11, 2024 | 303.46M |
| April 10, 2024 | 301.99M |
| April 09, 2024 | 303.46M |
| April 08, 2024 | 301.99M |
| April 05, 2024 | 304.19M |
| April 04, 2024 | 308.59M |
| April 03, 2024 | 324.72M |
| April 02, 2024 | 307.12M |
| April 01, 2024 | 306.39M |
| Date | Value |
|---|---|
| March 28, 2024 | 315.92M |
| March 27, 2024 | 304.19M |
| March 26, 2024 | 301.26M |
| March 25, 2024 | 310.06M |
| March 22, 2024 | 324.72M |
| March 21, 2024 | 324.72M |
| March 20, 2024 | 333.88M |
| March 19, 2024 | 395.09M |
| March 18, 2024 | 407.55M |
| March 15, 2024 | 450.06M |
| March 14, 2024 | 388.49M |
| March 13, 2024 | 402.42M |
| March 12, 2024 | 377.49M |
| March 11, 2024 | 365.77M |
| March 08, 2024 | 361.37M |
| March 07, 2024 | 420.01M |
| March 06, 2024 | 372.36M |
| March 05, 2024 | 310.79M |
| March 04, 2024 | 310.06M |
| March 01, 2024 | 314.46M |
| February 29, 2024 | 255.17M |
| February 28, 2024 | 253.80M |
| February 27, 2024 | 222.96M |
| February 26, 2024 | 198.98M |
| February 23, 2024 | 179.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
62.73M
Minimum
Mar 16 2020
450.06M
Maximum
Mar 15 2024
156.59M
Average
143.77M
Median
May 07 2019
Enterprise Value Benchmarks
| Lifecore Biomedical Inc | -- |
| Harrow Inc | 467.11M |
| Akebia Therapeutics Inc | 278.90M |
| 89bio Inc | 323.90M |
| Geron Corp | 1.971B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.111M |
| Revenue (Quarterly) | 13.21M |
| Total Expenses (Quarterly) | 17.12M |
| EPS Diluted (Quarterly) | -0.1341 |
| Gross Profit Margin (Quarterly) | 64.57% |
| Profit Margin (Quarterly) | -61.42% |
| Earnings Yield | -4.38% |
| Normalized Earnings Yield | -3.898 |